Earnings
UL Solutions Drops to 52-Week Low Despite Strong Q2 Earnings
UL Solutions hit $66.16, a 52-week trough, even as the firm reported record adjusted EBITDA and beat on earnings in its second quarter.
Navigator Holdings Hits 52-Week High as Q2 Results Smash Estimates
Maritime shipping firm posts second-quarter profit of $53 million and EPS of $0.85, well above expectations, as shares touch fresh highs.
Guardant Health Shares Surge to 52-Week High After Strong Quarter
Guardant Health stock hit a new 52-week high of $176.68 after reporting second-quarter revenue of $335 million, driven by robust demand for its Shield and G360 products.
UnitedHealthcare's Turnaround Gains Traction at Wells Fargo Conference
UnitedHealthcare reported positive progress in its turnaround efforts at the Wells Fargo Healthcare Conference, with strong revenue growth and strategic initiatives driving optimism for future performance.
Palladyne AI posts Q2 2026 revenue of $5.8m, guides $24‑27m full-year
The AI firm reported a 63% sequential revenue rise, $13 million in new contracts and a $25 million backlog, while targeting $24‑27 million in 2026 sales.
LifeStance Health Focuses on Growth and Margins at Morgan Stanley Conference
LifeStance Health reports strong revenue growth and targets mid-teens EBITDA margins by 2028, with a focus on expanding its clinician network and improving margins.
Universal Health Services projects 3% EBITDA growth despite policy headwinds
UHS sees 3% EBITDA and 6% EPS growth for 2026, but flags higher exchange‑coverage costs and potential Medicaid cuts as it expands its hospital network and virtual‑care platform.
ResMed Reports Growth, Margins, and GLP-1 Tailwind at Morgan Stanley Conference
ResMed Inc. outlined fiscal 2027 guidance, including 5-7% core revenue growth and 12-14% core EPS growth, at the Morgan Stanley Healthcare Conference. The company highlighted its gross margin expansion and the tailwind effect of GLP-1 data.
ZoomInfo Chief Financial Officer Graham O'Brien Discusses Strategic Shifts
ZoomInfo CFO Graham O'Brien outlines strategic shifts as the company moves upmarket and diversifies its revenue mix at Piper Sandler's Growth Frontiers Conference.
Roper Technologies Highlights AI Push and M&A Shift at Piper Sandler Conference
Roper Technologies (ROP) CEO and CFO discussed the company’s AI commercialization efforts and evolving M&A strategy, citing a pivot toward bolt-on acquisitions and a dedicated AI accelerator team.
CIBC ROE Hits 16.9%, Bank Eyes Steady Growth Through 2027
Canadian Imperial Bank of Commerce reported a return on equity of 16.9% year-to-date at a Barclays conference, exceeding its 15% target as commercial loan growth holds at 7% and CET1 ratio stands at 13.4%.
Columbia Banking System Shows Margin Expansion, Buyback Discipline at Barclays Conference
COLB reports NIM above 4%, $500M in buybacks, and steady commercial growth, while warning that competitive lending markets remain 'borderline irrational.'
CareDx Hits 52-Week High After Strong Second-Quarter Results
CareDx shares touched $53.71 as Q2 revenue of $132 million and adjusted EPS of $0.37 beat estimates, pushing the stock up more than 275% over a year.
Sight Sciences Returns to Growth on Glaucoma and Dry-Eye Platforms
Sight Sciences reported accelerating revenue growth and raised full-year guidance at the Morgan Stanley health-care conference, citing momentum across its OMNI glaucoma and TearCare dry-eye businesses.
NatWest lifts total income guidance to £17.9bn, eyes sub‑45% cost‑income ratio by 2028
NatWest Group raised its full‑year income target to £17.9bn, targets a cost‑income ratio below 45% by 2028 and reports strong capital generation and asset growth after the Evelyn Partners acquisition.
Alignment Health Keeps 2026 Guidance as Cost Headwinds Press Near-Term Results
The Medicare Advantage insurer held its full-year outlook steady despite institutional acute-care pressures, while coiling $240M in embedded earnings power from its maturing membership base.
Timken Sets $8.50 EPS Target, $1.3B FCF Goal Through 2028 at Jefferies Conference
Timken outlined 2028 financial targets including mid-single-digit organic sales growth, 500 basis points of EBITDA margin expansion, and a belts divestiture expected by Q3.
Kimberly-Clark flags near‑term earnings pressure as growth plan unfolds
The consumer‑goods maker sees Q3 revenue dip and EPS fall in the low‑teens, while outlining longer‑term targets and the impact of its Arbex joint venture and Kenvue acquisition.
Journeo Posts 53% Revenue Growth in H1 2026, Eyes £80M Target
Transport technology firm Journeo reported a 53% revenue jump to £37.6m in the first half of 2026, driven by acquisitions and a growing UK transit contract pipeline.
UroGen Reports $50.4 Million in Zusduri Revenue as Launch Gains Momentum
UroGen's Zusduri posted 73% sequential revenue growth in Q2, while the company outlined pipeline timelines for UGN-103 and UGN-104.
Regions Financial outlines growth plan and guidance at Barclays conference
Regions Financial Corp projected modest NII growth, a 3.70% net interest margin and a $90‑$105 million quarterly capital‑markets target while expanding branches and technology productivity.
ING Raises ROE Targets, Sees Steady Growth at Barclays Conference
Dutch lender lifts full-year and 2027 return-on-equity guidance above 15% and 16% respectively, citing strong deposit growth and expanding margins.
SEALSQ Misses H1 Revenue View as Losses Widen to $27.8 Million
SEALSQ reported H1 revenue of $11M against $14.9M forecasts, with net loss widening to $27.8M from $20M a year earlier, despite gross profit tripling year-over-year.
Novartis Shares Plunge 12% After Dystrophy Drug Del-desiran Misses Phase 3
Novartis stock fell sharply after its $12B Avidity asset del-desiran failed its Phase 3 HARBOR trial in myotonic dystrophy type 1, ceding frontrunner status to Dyne Therapeutics.